Loading...
Market
Will KERENDIA® achieve blockbuster sales status in 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Bayer's financial reports and sales data
Story
Bayer's Finerenone Achieves Primary Endpoint in Phase III HFmrEF and HFpEF Study
Aug 5, 2024, 06:40 AM
Bayer has announced that its Phase III FINEARTS-HF cardiovascular outcomes study investigating KERENDIA® (finerenone) in patients with heart failure with mildly reduced or preserved ejection fraction has achieved its primary endpoint. The study showed that finerenone, a non-steroidal MRA, demonstrated definitive cardiovascular benefits in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF), including reductions in CVd+total HF events. The results are seen as key to unlocking blockbuster sales for the drug. Full results will be presented at the upcoming ESC Congress.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $250 million • 25%
$250 million to $499 million • 25%
$500 million to $749 million • 25%
$750 million or more • 25%